ClinicalTrials.gg

Muscular Atrophy, Spinal clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 282 studies for Muscular Atrophy, Spinal across more than 10 countries. 71 are recruiting or about to start. 204 of them are mainly about Muscular Atrophy, Spinal (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 2 narrower conditions too, such as Spinal Muscular Atrophies of Childhood: 361 studies, 91 open.

Status

Completed
131
Recruiting
56
Active, not recruiting
33
Status unknown
24
Terminated
12
Not yet recruiting
11

Phase

Phase 2
40
Phase 3
26
Phase 1
24
Phase 4
8
Early Phase 1
3

Where

United States
121
Italy
41
France
39
Germany
37
United Kingdom
34
Canada
29

Who develops what

Add Muscular Atrophy, Spinal to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 7 programs from 6 companies, 6 with this as their studies’ main aim; 2 with a live phase 3 study; 1 primary completion in the next 12 months. Compare argenx, Biogen and Novartis here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
RisdiplamRecent, limited
Evidence
  • NCT07047144 · Scholar Rock, Inc. · Phase 2 · live · background · “Risdiplam” · registered Apr 2025
Hoffmann-La Roche100% of its industry studiesUS: Hoffmann-La Roche (FDA 2020)EU: Hoffmann-La Roche (EMA 2021)11 study
nusinersenRecent, limited
Evidence
  • NCT07047144 · Scholar Rock, Inc. · Phase 2 · live · background · “Nusinersen” · registered Apr 2025
Biogen100% of its industry studiesUS: Biogen (FDA 2016)EU: Biogen (EMA 2017)11 study

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
salanersen☆ Track3 live phase-3 studies: NCT07444476, NCT07221669, NCT07444450Biogen

The 1 in phase 3 with the nearest primary completion, of 7 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 30 Oct 2027 est.vesemnogene lantuparvovec · Lantu Biopharma · Phase 2 main aimNCT06288230 An Open Label Study of Gene Therapy Product (Vesemnogene Lantuparvovec) in Spinal Muscular Atrophy — primary endpoint: Numbers of participants with adverse events (AEs), serious adverse events (SAEs) · 20 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Muscular Atrophy, Spinal studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Coming up

30studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 56 Muscular Atrophy, Spinal studies recruiting now, 28 (50%) set no upper age limit and 25 (45%) stop at 75 or younger. 44 (79%) take children under 18. 1 (2%) are for women only and 1 (2%) for men only; 11 (20%) take healthy volunteers.

Recruiting studies that take each age, of 56
AgeWomenMen
1027 (48%)27 (48%)
1839 (70%)39 (70%)
3037 (66%)37 (66%)
4037 (66%)37 (66%)
5037 (66%)37 (66%)
6534 (61%)34 (61%)
7532 (57%)32 (57%)
8530 (54%)30 (54%)

Across all 282 studies, recruiting or not: 57% stop at 75 or younger and 52% at 65; 79% take children; 1% are for women only and 1% for men only; 21% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Muscular Atrophy, Spinal studies take

Of 18 phase 3 interventional studies under Muscular Atrophy, Spinal, half reached primary completion within 33 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 234 mo25–42 · 15 studies——
Phase 333 mo24–63 · 18 studies——
Interventional, no phase27 mo17–51 · 58 studies—28 mo19–52 · 49 studies
Observational88 mo36–… · 58 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 282. Browse all 282 → or search them.